|By PR Newswire||
|March 3, 2014 05:02 PM EST||
NEW YORK, March 3, 2014 /PRNewswire/ -- New Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Perspectives: Innovation within the Biopharma Industry
What does innovation mean within the biopharma industry? How much you spend on R&D? How many products you bring to market? How many New Molecular Entities (NME) you have in research?
Within the biopharma industry, R&D output is at odds with R&D investment. Between 1950 and 2010, the number of new molecules (including both biologics and small molecules) brought to market by the biopharma industry, per billion dollars of R&D expenditure, fell by a factor of 100 in inflation adjusted terms. Innovation, it seems, is getting increasingly expensive while the prospect of blockbuster income to pay for it is getting rarer. Something has to change.
So...what are the issues we need to consider?
- New molecular entity (NME) output is not an accurate reflection of the state of innovation: new ways of measuring innovation within the biopharma industry are needed. Current methods of measuring NME output from either the FDA or EMA provide only a snapshot of what regulatory agencies deem approvable. The industry needs to move beyond NME output as a measure of innovation, taking into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society;
- Collaboration is critical to success: Industry must leverage the experience, skills and insights from a diverse range of stakeholders such as physicians, patients and payers – this is critical to the future of innovation. But collaboration needs to be smart. Biopharma companies must collaborate only when the expected outcome adds value to society, contributes to better patient outcomes and supports commercial goals;
- Companies need to be brave: constantly mining a 'comfort zone' of known approaches leads to complacency and limits innovation. While many believe that all of the 'low hanging fruit' have been taken there is another perspective: that there is plenty of fruit left on the tree and companies just need the bravery and vision to look for them.
This FirstView advisory report – the first in a major new series – provides everyone interested in the dynamics of biopharma innovation with a robust understanding of the issues, opinions and insights that are shaping the current environment, and the events that could lead to a change in the future. Every aspect of the report is informed by expert insight gathered from 60-minute interviews with 16 key opinion leaders (KOLs), payers and senior industry executives from leading companies from across Europe and the US.
Experts share their insights on...
- The impact of innovation within biotechnology over the last 15-20 years- A view of what a world without biologics would have looked like
- The pros and cons of biological therapies
- Where biologics have been best received and where there is still resistance
- The role that industry played, and needs to play, within the 'innovation ecosystem'
- The important and growing roles of key stakeholder groups
- Attitudes toward innovation within industry
- New technologies and innovations that are exciting industry at the moment, and hypotheses about the future of innovation and roles in driving it forward
- This report tackles the pressing innovation issues and questions
What does biopharma innovation mean?
- Where is innovation coming from?
- How can the lessons of the last few decades be used to guide future biopharma innovation?
- What will be the future trends in biopharma innovation?
- How has biopharma innovation been measured in the past, and do new ways of measuring innovation need to be developed?
- What must biopharma companies focus on in order to remain competitive and deliver innovation that is truly valued by society?
- Which companies are currently viewed as being leaders of innovation within the pharmaceutical industry?
- What disruptive technologies and market dynamics are likely to impact the rate of innovation within the biopharma industry?
- What do KOLs, payers and industry stakeholders view as critical for biopharma companies to focus on in order to maintain shareholder returns and deliver customer value?
Whether you work in big pharma, a drug discovery company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment of how we can better cost-effectively develop and bring biopharmaceuticals to the market in a timely manner.
- Understand and evaluate the current status of innovation within the biopharma industry, including the key drivers and resistors of innovation
- Get up to speed with current thinking on how innovation is measured within the biopharma industry
- Know what potential changes need to be made in terms of how innovation will be assessed in the future
- Understand clinical, payer and industry opinions of current and future market dynamics
- Appreciate what the critical opportunities biopharma companies should be investing in and how these opportunities can be realised
Selected Quotes from the Report
'Innovation [within pharma] is a lot like a fine Swiss watch. There are multiple moving parts but if you take one part out, the watch stops. So every part in that watch is absolutely critical to the functioning of that watch in the same way that every key stakeholder group within the innovation ecosystem has a critical role. Whether it be a payer, a physician, a company, a policy maker, a scientist, etc. They all have a role to play and if they stop playing that role, the system falls over.' Former Head of Innovation, Eli Lilly.
'Collaboration is your key for survival for the future. You cannot always count on the old model of finding solutions inside your own company.' Global Head of External Innovation & Strategic Partnerships, Roche.
'If we had a shorter, faster, more efficient regulatory system, then the cost [and time taken] to complete clinical trials would go down. I think we need to re-think how it could be smarter, more efficient. At the moment, the regulatory system is set up to benefit big pharma, not smaller companies.' Scientific Advisor, Innogen Institute.
'My view is that biopharma companies need to be more receptive to new models of innovation, and that includes more collaborations, more discussions, sharing of data. I'm not a big believer of we [the biopharma industry] are better than everyone else and we know better, so I think that being open to the environment is really important.' Head of Innovation at Merck Serono.
'Do we have a secret sauce [when it comes to innovation]? I don't know. I think it's the willingness to take a little bit of risk in that space. I think understanding that as good as we have been in the past, it wasn't enough. We knew that that landscape was clearly changing and under some great leadership, we were able to move into a completely new system. Good people like to follow good leaders so that's certainly a part of it.' VP Strategy & Operations, Janssen R&D.
'My personal opinion is that the time of the very, very large pharma companies is maybe already over. They're not dynamic enough to react very quickly to changing and dynamic patient needs, so smaller conglomerates of people who throw their expertise into one bucket and do that quickly might win over large pharma companies.' Senior Manager, Boehringer Ingelheim.
Experts interviewed for this report
This report benefits from the considered insight of leading clinicians, payers and senior industry experts. These include:
KOL's with relevant clinical, regulatory, scientific and commercial experience, scientific publications, involvement in clinical trials and their record of presenting at high profile international conferences.
Payers with relevant (and recent) experience of deciding on the reimbursement of expensive biological therapies in areas such as oncology, inflammatory conditions, orphan diseases and infectious diseases.
Senior industry executives with current (or recent) experience in innovation, strategy, business development, licensing, competitive intelligence and long-term planning.
Their names have been kept confidential to provide contributors with a secure forum in which they could share their candid opinions and views.
Key Opinion Leaders
Director, Managed Care Organization
Former Pharmacy Director, Harvard Pilgrim Health
Director, Health Insurance (Germany)
Head of Medicines Management, CCG (UK)
Former Head of Innovation at Eli Lilly
Senior Manager, Boehringer Ingelheim
Head of Innovation, Merck Serono
Scientific Advisor, Innogen Institute
VP Strategy & Operations, Janssen R&D
Global Head, Innovation & Partnerships, Roche
Two senior executives from a large EU-based biotech firm
Who should read this report, and why?
FirstView's Stakeholder Perspectives: Innovation within the Biopharma Industry is a 'must read' for industry executives working in the areas of innovation strategy, business development & licensing, competitive intelligence, long-term planning, market access, R&D, partnering & alliance management, and emerging markets. Each stakeholder group will be able to use the insight delivered in the report to:
- Review aims, objectives and goals of current innovation strategy, and what (on the basis of the way the market is evolving) will be the critical success factors for future success;
- Reassess business development and licensing needs, aims and objectives to ensure that all future deals are accretive in terms of their ability to deliver innovative products to the market;
- Review external competitor strategies with a view to ensuring internal stakeholders are kept up to speed with market and competitive developments;
- Perform internal scenario analyses of various opportunities (e.g. gene therapy, regenerative medicine and technology opportunities) to see what will be needed to leverage the opportunity, and to understand what potential future business models will be needed;
- Review relationships with payers, asking the question 'are we providing the right data to payers for our innovative products'?
- Review current clinical trial strategies to improve the effectiveness of clinical trials, making them faster, smarter and cheaper, and review regulatory strategies based on increased regulatory hurdles;
- Get a better understanding of what critical attributes are needed in partners when assessing collaborations and joint ventures;
- Engage in portfolio optimisation work in emerging markets to ensure that needs of the market are being addressed by current portfolio; if not, review opportunities to in-license, partner, divest assets.
About FirstView Reports
FirstWord's FirstView Stakeholder Perspectives: Innovation within the Biopharma Industry is the first of a new series of authoritative analyses that focus on the drivers and resistors of innovation within the biopharma industry.
Innovation is the life blood of the industry, yet the cost of developing and bringing new products to market is spiralling. The series will forensically examine and answer fundamental questions such as:
- As the market moves away from blockbusters to 'niche-busters', how can industry and regulators bring new products to market that are not only safe and effective, but also affordable?
- Is the current clinical trials system still fit for purpose, or does industry and the regulators need to develop innovative, more efficient ways of establishing the clinical utility of new medicines?
- Are the advances in personalised medicine already witnessed only the tip of the iceberg, or have we seen all there is to offer in the field of stratified medicine?
- Are biosimilars set to take the market by storm and deliver on the promise of high quality, affordable biologics for all, or will the sector crumble under the weight of its own expectations?
- 'Beyond the Pill.' Do you have a strategy? Do you need one? And how influential will payers be when it comes to the impact of 'beyond the pill' solutions on biopharma revenues?
The pharmaceutical industry is on the verge of significant change. Old biopharma business models are under significant stress, and things need to change. Make sure you understand the potential strategic implications of these upcoming changes with FirstWord's FirstView Reports!
2.Research methodology, aims and objectives
3.Innovation within the biopharma industry
3.1.A review and analysis of the defining characteristics of today's biopharma industry, and how they are effecting innovation
3.2.The measurement and benchmarking of innovation within the biopharma industry, and some views on the key drivers and resistors of innovation
4.Key stakeholders in the innovation ecosystem
4.1.Who they are, and what their roles must be in order to drive innovation
4.2.Future perspectives on how each key stakeholder group must learn to work together more closely
5.Opportunities for biopharma companies, both now and in the future
5.1.A review and analysis of some of the key opportunities biopharma companies should be investing in to drive future growth, including 'beyond the pill' strategies, biosimilars, cancer immunotherapy, gene therapy, regenerative medicine, personalised medicine and networks.
6.A scenario-based analysis of potential biopharma futures
6.1An overview of scenarios, and how they can be used to analyse potential future market dynamics
6.2.The critical scenario drives of this report, and how they were devised
6.3.Four potential scenarios, with a robust review of each scenario in terms of its potential implications to the key stakeholders within the innovation ecosystem
6.4.Expert views and insight on the scenarios, and what it could mean for biopharma companies.
To order this report: Stakeholder Perspectives: Innovation within the Biopharma Industry
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
May. 4, 2016 09:00 PM EDT Reads: 1,394
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
May. 4, 2016 07:30 PM EDT Reads: 1,690
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., will focus on real world deployments of DDoS mitigation strategies in every layer of the network. He will give an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He will also outline what we have found in our experience managing and running thousands of Linux and Unix managed service platforms and what specifically c...
May. 4, 2016 07:00 PM EDT Reads: 1,305
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
May. 4, 2016 07:00 PM EDT Reads: 1,268
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
May. 4, 2016 05:30 PM EDT Reads: 1,380
The demand for organizations to expand their infrastructure to multiple IT environments like the cloud, on-premise, mobile, bring your own device (BYOD) and the Internet of Things (IoT) continues to grow. As this hybrid infrastructure increases, the challenge to monitor the security of these systems increases in volume and complexity. In his session at 18th Cloud Expo, Stephen Coty, Chief Security Evangelist at Alert Logic, will show how properly configured and managed security architecture can...
May. 4, 2016 05:15 PM EDT Reads: 385
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
May. 4, 2016 05:00 PM EDT Reads: 1,318
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
May. 4, 2016 04:30 PM EDT Reads: 823
A critical component of any IoT project is the back-end systems that capture data from remote IoT devices and structure it in a way to answer useful questions. Traditional data warehouse and analytical systems are mature technologies that can be used to handle large data sets, but they are not well suited to many IoT-scale products and the need for real-time insights. At Fuze, we have developed a backend platform as part of our mobility-oriented cloud service that uses Big Data-based approache...
May. 4, 2016 03:30 PM EDT Reads: 627
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
May. 4, 2016 03:00 PM EDT Reads: 1,049
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
May. 4, 2016 03:00 PM EDT Reads: 1,175
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
May. 4, 2016 02:00 PM EDT Reads: 1,284
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
May. 4, 2016 02:00 PM EDT Reads: 1,224
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
May. 4, 2016 01:45 PM EDT Reads: 1,338